Global Human Rabies Immunoglobulin (IM) Market Insights and Forecast to 2027

1 Study Coverage

• 1.1 Human Rabies Immunoglobulin (IM) Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Human Rabies Immunoglobulin (IM) Market Size Growth Rate by Type
  • 1.4.2 ERIG
  • 1.4.3 HRIG
• 1.3 Market by Application
  • 1.3.1 Global Human Rabies Immunoglobulin (IM) Market Size Growth Rate by Application
  • 1.3.2 Category II Exposure
  • 1.3.3 Category III Exposure
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global Human Rabies Immunoglobulin (IM) Sales Estimates and Forecasts 2016-2027
• 2.2 Global Human Rabies Immunoglobulin (IM) Revenue Estimates and Forecasts 2016-2027
• 2.3 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2016 VS 2021 VS 2027
• 2.4 Global Top Human Rabies Immunoglobulin (IM) Regions by Sales
  • 2.4.1 Global Top Human Rabies Immunoglobulin (IM) Regions by Sales (2016-2021)
  • 2.4.2 Global Top Human Rabies Immunoglobulin (IM) Regions by Sales (2022-2027)
• 2.5 Global Top Human Rabies Immunoglobulin (IM) Regions by Revenue
  • 2.5.1 Global Top Human Rabies Immunoglobulin (IM) Regions by Revenue (2016-2021)
  • 2.5.2 Global Top Human Rabies Immunoglobulin (IM) Regions by Revenue (2022-2027)
• 2.6 North America
• 2.7 Europe
• 2.8 Asia-Pacific
• 2.9 Latin America
• 2.10 Middle East & Africa

3 Competition by Manufacturers

• 3.1 Global Human Rabies Immunoglobulin (IM) Sales by Manufacturers
  • 3.1.1 Global Top Human Rabies Immunoglobulin (IM) Manufacturers by Sales (2016-2021)
  • 3.1.2 Global Top Human Rabies Immunoglobulin (IM) Manufacturers Market Share by Sales (2016-2021)
  • 3.1.3 Global Top 10 and Top 5 Companies by Human Rabies Immunoglobulin (IM) Sales in 2020
• 3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Manufacturers
  • 3.2.1 Global Top Human Rabies Immunoglobulin (IM) Manufacturers by Revenue (2016-2021)
  • 3.2.2 Global Top Human Rabies Immunoglobulin (IM) Manufacturers Market Share by Revenue (2016-2021)
  • 3.2.3 Global Top 10 and Top 5 Companies by Human Rabies Immunoglobulin (IM) Revenue in 2020
• 3.3 Global Human Rabies Immunoglobulin (IM) Sales Price by Manufacturers
• 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Human Rabies Immunoglobulin (IM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global Human Rabies Immunoglobulin (IM) Manufacturers Geographical Distribution
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Human Rabies Immunoglobulin (IM) Sales by Type
  • 4.1.1 Global Human Rabies Immunoglobulin (IM) Historical Sales by Type (2016-2021)
  • 4.1.2 Global Human Rabies Immunoglobulin (IM) Forecasted Sales by Type (2022-2027)
  • 4.1.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2016-2027)
• 4.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type
  • 4.2.1 Global Human Rabies Immunoglobulin (IM) Historical Revenue by Type (2016-2021)
  • 4.2.2 Global Human Rabies Immunoglobulin (IM) Forecasted Revenue by Type (2022-2027)
  • 4.2.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2016-2027)
• 4.3 Global Human Rabies Immunoglobulin (IM) Price by Type
  • 4.3.1 Global Human Rabies Immunoglobulin (IM) Price by Type (2016-2021)
  • 4.3.2 Global Human Rabies Immunoglobulin (IM) Price Forecast by Type (2022-2027)

5 Market Size by Application

• 5.1 Global Human Rabies Immunoglobulin (IM) Sales by Application
  • 5.1.1 Global Human Rabies Immunoglobulin (IM) Historical Sales by Application (2016-2021)
  • 5.1.2 Global Human Rabies Immunoglobulin (IM) Forecasted Sales by Application (2022-2027)
  • 5.1.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2016-2027)
• 5.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application
  • 5.2.1 Global Human Rabies Immunoglobulin (IM) Historical Revenue by Application (2016-2021)
  • 5.2.2 Global Human Rabies Immunoglobulin (IM) Forecasted Revenue by Application (2022-2027)
  • 5.2.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2016-2027)
• 5.3 Global Human Rabies Immunoglobulin (IM) Price by Application
  • 5.3.1 Global Human Rabies Immunoglobulin (IM) Price by Application (2016-2021)
  • 5.3.2 Global Human Rabies Immunoglobulin (IM) Price Forecast by Application (2022-2027)

6 North America

• 6.1 North America Human Rabies Immunoglobulin (IM) Market Size by Type
  • 6.1.1 North America Human Rabies Immunoglobulin (IM) Sales by Type (2016-2027)
  • 6.1.2 North America Human Rabies Immunoglobulin (IM) Revenue by Type (2016-2027)
• 6.2 North America Human Rabies Immunoglobulin (IM) Market Size by Application
  • 6.2.1 North America Human Rabies Immunoglobulin (IM) Sales by Application (2016-2027)
  • 6.2.2 North America Human Rabies Immunoglobulin (IM) Revenue by Application (2016-2027)
• 6.3 North America Human Rabies Immunoglobulin (IM) Market Size by Country
  • 6.3.1 North America Human Rabies Immunoglobulin (IM) Sales by Country (2016-2027)
  • 6.3.2 North America Human Rabies Immunoglobulin (IM) Revenue by Country (2016-2027)
  • 6.3.3 U.S.
  • 6.3.4 Canada

7 Europe

• 7.1 Europe Human Rabies Immunoglobulin (IM) Market Size by Type
  • 7.1.1 Europe Human Rabies Immunoglobulin (IM) Sales by Type (2017-2027)
  • 7.1.2 Europe Human Rabies Immunoglobulin (IM) Revenue by Type (2017-2027)
• 7.2 Europe Human Rabies Immunoglobulin (IM) Market Size by Application
  • 7.2.1 Europe Human Rabies Immunoglobulin (IM) Sales by Application (2017-2027)
  • 7.2.2 Europe Human Rabies Immunoglobulin (IM) Revenue by Application (2017-2027)
• 7.3 Europe Human Rabies Immunoglobulin (IM) Market Size by Country
  • 7.3.1 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2017-2027)
  • 7.3.2 Europe Human Rabies Immunoglobulin (IM) Revenue by Country (2017-2027)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia

8 Asia Pacific

• 8.1 Asia Pacific Human Rabies Immunoglobulin (IM) Market Size by Type
  • 8.1.1 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Type (2018-2027)
  • 8.1.2 Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Type (2018-2027)
• 8.2 Asia Pacific Human Rabies Immunoglobulin (IM) Market Size by Application
  • 8.2.1 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Application (2018-2027)
  • 8.2.2 Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Application (2018-2027)
• 8.3 Asia Pacific Human Rabies Immunoglobulin (IM) Market Size by Region
  • 8.3.1 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Region (2018-2027)
  • 8.3.2 Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Region (2018-2027)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia
  • 8.3.12 Philippines

9 Latin America

• 9.1 Latin America Human Rabies Immunoglobulin (IM) Market Size by Type
  • 9.1.1 Latin America Human Rabies Immunoglobulin (IM) Sales by Type (2019-2027)
  • 9.1.2 Latin America Human Rabies Immunoglobulin (IM) Revenue by Type (2019-2027)
• 9.2 Latin America Human Rabies Immunoglobulin (IM) Market Size by Application
  • 9.2.1 Latin America Human Rabies Immunoglobulin (IM) Sales by Application (2019-2027)
  • 9.2.2 Latin America Human Rabies Immunoglobulin (IM) Revenue by Application (2019-2027)
• 9.3 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country
  • 9.3.1 Latin America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2027)
  • 9.3.2 Latin America Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2027)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina

6 Middle East and Africa

• 6.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Type
  • 6.1.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Type (2016-2027)
  • 6.1.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Type (2016-2027)
• 6.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Application
  • 6.2.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Application (2016-2027)
  • 6.2.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Application (2016-2027)
• 6.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country
  • 6.3.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2016-2027)
  • 6.3.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country (2016-2027)
  • 6.3.3 Turkey
  • 6.3.4 Saudi Arabia
  • 6.3.5 U.A.E

11 Company Profiles

• 11.1 CSL Behring
  • 11.1.1 CSL Behring Corporation Information
  • 11.1.2 CSL Behring Overview
  • 11.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Description
  • 11.1.5 CSL Behring Related Developments
• 11.2 Grifols
  • 11.2.1 Grifols Corporation Information
  • 11.2.2 Grifols Overview
  • 11.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Description
  • 11.2.5 Grifols Related Developments
• 11.3 Sanofi
  • 11.3.1 Sanofi Corporation Information
  • 11.3.2 Sanofi Overview
  • 11.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Description
  • 11.3.5 Sanofi Related Developments
• 11.4 Sichuan Yuanda Shuyang
  • 11.4.1 Sichuan Yuanda Shuyang Corporation Information
  • 11.4.2 Sichuan Yuanda Shuyang Overview
  • 11.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Description
  • 11.4.5 Sichuan Yuanda Shuyang Related Developments
• 11.5 CNBG
  • 11.5.1 CNBG Corporation Information
  • 11.5.2 CNBG Overview
  • 11.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Description
  • 11.5.5 CNBG Related Developments
• 11.6 Kamada
  • 11.6.1 Kamada Corporation Information
  • 11.6.2 Kamada Overview
  • 11.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Description
  • 11.6.5 Kamada Related Developments
• 11.7 CBPO
  • 11.7.1 CBPO Corporation Information
  • 11.7.2 CBPO Overview
  • 11.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Description
  • 11.7.5 CBPO Related Developments
• 11.8 Shuanglin Bio
  • 11.8.1 Shuanglin Bio Corporation Information
  • 11.8.2 Shuanglin Bio Overview
  • 11.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Description
  • 11.8.5 Shuanglin Bio Related Developments
• 11.9 Weiguang Bio
  • 11.9.1 Weiguang Bio Corporation Information
  • 11.9.2 Weiguang Bio Overview
  • 11.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Description
  • 11.9.5 Weiguang Bio Related Developments
• 11.10 Shanghai RAAS
  • 11.10.1 Shanghai RAAS Corporation Information
  • 11.10.2 Shanghai RAAS Overview
  • 11.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Description
  • 11.10.5 Shanghai RAAS Related Developments
• 11.1 CSL Behring
  • 11.1.1 CSL Behring Corporation Information
  • 11.1.2 CSL Behring Overview
  • 11.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Description
  • 11.1.5 CSL Behring Related Developments
• 11.12 VINS
  • 11.12.1 VINS Corporation Information
  • 11.12.2 VINS Overview
  • 11.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.12.4 VINS Product Description
  • 11.12.5 VINS Related Developments

12 Value Chain and Sales Channels Analysis

• 12.1 Human Rabies Immunoglobulin (IM) Value Chain Analysis
• 12.2 Human Rabies Immunoglobulin (IM) Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Human Rabies Immunoglobulin (IM) Production Mode & Process
• 12.4 Human Rabies Immunoglobulin (IM) Sales and Marketing
  • 12.4.1 Human Rabies Immunoglobulin (IM) Sales Channels
  • 12.4.2 Human Rabies Immunoglobulin (IM) Distributors
• 12.5 Human Rabies Immunoglobulin (IM) Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

• 13.1 Human Rabies Immunoglobulin (IM) Industry Trends
• 13.2 Human Rabies Immunoglobulin (IM) Market Drivers
• 13.3 Human Rabies Immunoglobulin (IM) Market Challenges
• 13.4 Human Rabies Immunoglobulin (IM) Market Restraints

14 Key Findings in The Global Human Rabies Immunoglobulin (IM) Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details